uniQure Faces Class Action Lawsuit Over Misleading Statements
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy QURE?
Source: Globenewswire
- Class Action Filed: Berger Montague PC has announced a class action lawsuit against uniQure on behalf of investors who acquired securities between September 24, 2025, and October 31, 2025, highlighting significant investor concerns regarding the company's transparency.
- Stock Price Volatility: On September 24, 2025, uniQure's stock surged from $13.66 to $47.50, a nearly 250% increase, but plummeted over 49% to $34.29 on November 3, 2025, after news that FDA agreement on study design was not finalized, indicating a loss of market confidence.
- FDA Approval Uncertainty: The lawsuit alleges that uniQure misled investors about the effectiveness of its gene therapy candidate AMT-130 and the likelihood of accelerated FDA approval, resulting in significant financial losses for investors who made decisions based on misleading information.
- Investor Rights Protection: Investors must apply by April 13, 2026, to be appointed as lead plaintiffs in the class action, reflecting a growing emphasis on corporate governance and transparency that could impact future investor confidence and the company's reputation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy QURE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on QURE
Wall Street analysts forecast QURE stock price to rise
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 22.370
Low
33.00
Averages
49.88
High
70.00
Current: 22.370
Low
33.00
Averages
49.88
High
70.00
About QURE
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
uniQure Faces Class Action Lawsuit Over Misleading Statements
- Class Action Filed: Berger Montague PC has announced a class action lawsuit against uniQure on behalf of investors who acquired securities between September 24, 2025, and October 31, 2025, highlighting significant investor concerns regarding the company's transparency.
- Stock Price Volatility: On September 24, 2025, uniQure's stock surged from $13.66 to $47.50, a nearly 250% increase, but plummeted over 49% to $34.29 on November 3, 2025, after news that FDA agreement on study design was not finalized, indicating a loss of market confidence.
- FDA Approval Uncertainty: The lawsuit alleges that uniQure misled investors about the effectiveness of its gene therapy candidate AMT-130 and the likelihood of accelerated FDA approval, resulting in significant financial losses for investors who made decisions based on misleading information.
- Investor Rights Protection: Investors must apply by April 13, 2026, to be appointed as lead plaintiffs in the class action, reflecting a growing emphasis on corporate governance and transparency that could impact future investor confidence and the company's reputation.
See More
Class Action Lawsuit Filed Against uniQure N.V.
- Class Action Initiation: Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased uniQure N.V. shares between September 24 and October 31, 2025, with a deadline of April 13, 2026, for potential lead plaintiffs, highlighting the urgency and compensation opportunities for affected investors.
- Lawsuit Background: The lawsuit alleges that uniQure failed to disclose that its pivotal study design for a leading drug candidate was not fully approved by the FDA, leading to a lack of reasonable basis for investors' assessments of the company's prospects, potentially resulting in financial losses.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its strength and experience in handling similar cases effectively.
- Investor Action Guidance: Investors can obtain more information by visiting the designated website or calling a toll-free number, emphasizing the ease of participation in the class action and the potential legal support available, encouraging investors to take action to protect their rights.
See More
uniQure Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action against uniQure N.V. on behalf of investors who purchased shares between September 24 and October 31, 2025, indicating a significant loss of investor confidence in the company's performance.
- Stock Price Volatility: On September 24, 2025, uniQure's stock surged from $13.66 to $47.50, a nearly 250% increase, but plummeted 49% to $34.29 on November 3, 2025, after the FDA expressed doubts about the approval prospects for AMT-130, highlighting the market's uncertainty regarding the company's future.
- Clinical Trial Issues: The FDA did not fully approve the design of uniQure's pivotal study for AMT-130, leading to shaken investor confidence in the BLA submission timeline, which reflects significant risks in the company's R&D and regulatory compliance.
- Investor Rights: Investors may seek to be appointed as lead plaintiffs in the class action by April 13, 2026, underscoring the importance of protecting investor rights in securities fraud cases and the potential implications for uniQure's legal and financial outcomes.
See More
Investigation into uniQure Securities Litigation Announced
- Litigation Investigation: Faruq & Faruq, LLP is investigating potential claims against uniQure N.V. due to possible false statements made during securities transactions between September 24, 2025, and October 31, 2025, urging investors to contact them before the April 13, 2026 deadline to seek lead plaintiff status.
- FDA Approval Issues: uniQure is accused of failing to fully disclose that its pivotal study design was not fully approved by the FDA, leading to investor misconceptions about the company's prospects and potentially impacting its future Biologics License Application (BLA) process.
- Stock Price Plunge: On November 3, 2025, uniQure's stock price plummeted by 49%, from $67.69 to $34.29, following the FDA's statement that it no longer agreed with the adequacy of the data, indicating a severe loss of market confidence in the company's future.
- Investor Rights Protection: Faruq & Faruq encourages anyone with information regarding uniQure's conduct, including former employees and shareholders, to come forward to help protect investors' legal rights.
See More
uniQure Faces Class Action Lawsuit Reminder for Investors
- Class Action Notice: The Schall Law Firm reminds investors of a class action lawsuit against uniQure N.V. for violations of the Securities Exchange Act, concerning securities purchased between September 24, 2025, and October 31, 2025, with a deadline for participation set for April 13, 2026.
- False Statements Allegation: The complaint alleges that uniQure made false and misleading statements to the market, failing to secure full FDA approval for its pivotal study, which resulted in significant losses for investors once the truth was revealed, highlighting serious deficiencies in the company's disclosure practices.
- BLA Timeline Delays: uniQure is accused of misleading the market regarding its ability to submit a Biologics License Application (BLA) on time, indicating potential delays to supplement data submitted to the FDA, which directly undermined investor confidence.
- Investor Losses: As the market learned the truth about uniQure, investors faced substantial losses, prompting the Schall Law Firm to encourage affected shareholders to join the lawsuit for compensation, reflecting serious issues regarding the company's transparency and compliance.
See More
uniQURE Faces Class Action Lawsuit
- Lawsuit Background: Kirby McInerney LLP has announced a class action lawsuit on behalf of investors who acquired uniQURE N.V. securities between September 24, 2025, and October 31, 2025, alleging that the company failed to fully disclose FDA approval of its Pivotal Study design, potentially leading to investor losses.
- Stock Price Plunge: Following the disclosure on November 3, 2025, that the timeline for the BLA submission was unclear, uniQURE's stock price plummeted by $33.40, or approximately 49.33%, from $67.69 on October 31, 2025, reflecting strong market concerns about the company's future prospects.
- Investor Rights: Any investor who purchased shares during the class period can seek appointment as lead plaintiff in the class action lawsuit, with courts typically appointing those with the largest financial losses, ensuring that investor rights are protected throughout the legal process.
- Legal Consultation Opportunity: Kirby McInerney LLP offers no-cost legal consultations, encouraging affected investors to reach out to understand their rights and interests, indicating the firm's commitment to securing compensation for investors.
See More
uniQure Faces Class Action Lawsuit Over Misleading Statements
- Class Action Filed: Berger Montague PC has announced a class action lawsuit against uniQure on behalf of investors who acquired securities between September 24, 2025, and October 31, 2025, highlighting significant investor concerns regarding the company's transparency.
- Stock Price Volatility: On September 24, 2025, uniQure's stock surged from $13.66 to $47.50, a nearly 250% increase, but plummeted over 49% to $34.29 on November 3, 2025, after news that FDA agreement on study design was not finalized, indicating a loss of market confidence.
- FDA Approval Uncertainty: The lawsuit alleges that uniQure misled investors about the effectiveness of its gene therapy candidate AMT-130 and the likelihood of accelerated FDA approval, resulting in significant financial losses for investors who made decisions based on misleading information.
- Investor Rights Protection: Investors must apply by April 13, 2026, to be appointed as lead plaintiffs in the class action, reflecting a growing emphasis on corporate governance and transparency that could impact future investor confidence and the company's reputation.
See More
Class Action Lawsuit Filed Against uniQure N.V.
- Class Action Initiation: Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased uniQure N.V. shares between September 24 and October 31, 2025, with a deadline of April 13, 2026, for potential lead plaintiffs, highlighting the urgency and compensation opportunities for affected investors.
- Lawsuit Background: The lawsuit alleges that uniQure failed to disclose that its pivotal study design for a leading drug candidate was not fully approved by the FDA, leading to a lack of reasonable basis for investors' assessments of the company's prospects, potentially resulting in financial losses.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its strength and experience in handling similar cases effectively.
- Investor Action Guidance: Investors can obtain more information by visiting the designated website or calling a toll-free number, emphasizing the ease of participation in the class action and the potential legal support available, encouraging investors to take action to protect their rights.
See More
uniQure Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action against uniQure N.V. on behalf of investors who purchased shares between September 24 and October 31, 2025, indicating a significant loss of investor confidence in the company's performance.
- Stock Price Volatility: On September 24, 2025, uniQure's stock surged from $13.66 to $47.50, a nearly 250% increase, but plummeted 49% to $34.29 on November 3, 2025, after the FDA expressed doubts about the approval prospects for AMT-130, highlighting the market's uncertainty regarding the company's future.
- Clinical Trial Issues: The FDA did not fully approve the design of uniQure's pivotal study for AMT-130, leading to shaken investor confidence in the BLA submission timeline, which reflects significant risks in the company's R&D and regulatory compliance.
- Investor Rights: Investors may seek to be appointed as lead plaintiffs in the class action by April 13, 2026, underscoring the importance of protecting investor rights in securities fraud cases and the potential implications for uniQure's legal and financial outcomes.
See More
Investigation into uniQure Securities Litigation Announced
- Litigation Investigation: Faruq & Faruq, LLP is investigating potential claims against uniQure N.V. due to possible false statements made during securities transactions between September 24, 2025, and October 31, 2025, urging investors to contact them before the April 13, 2026 deadline to seek lead plaintiff status.
- FDA Approval Issues: uniQure is accused of failing to fully disclose that its pivotal study design was not fully approved by the FDA, leading to investor misconceptions about the company's prospects and potentially impacting its future Biologics License Application (BLA) process.
- Stock Price Plunge: On November 3, 2025, uniQure's stock price plummeted by 49%, from $67.69 to $34.29, following the FDA's statement that it no longer agreed with the adequacy of the data, indicating a severe loss of market confidence in the company's future.
- Investor Rights Protection: Faruq & Faruq encourages anyone with information regarding uniQure's conduct, including former employees and shareholders, to come forward to help protect investors' legal rights.
See More
uniQure Faces Class Action Lawsuit Reminder for Investors
- Class Action Notice: The Schall Law Firm reminds investors of a class action lawsuit against uniQure N.V. for violations of the Securities Exchange Act, concerning securities purchased between September 24, 2025, and October 31, 2025, with a deadline for participation set for April 13, 2026.
- False Statements Allegation: The complaint alleges that uniQure made false and misleading statements to the market, failing to secure full FDA approval for its pivotal study, which resulted in significant losses for investors once the truth was revealed, highlighting serious deficiencies in the company's disclosure practices.
- BLA Timeline Delays: uniQure is accused of misleading the market regarding its ability to submit a Biologics License Application (BLA) on time, indicating potential delays to supplement data submitted to the FDA, which directly undermined investor confidence.
- Investor Losses: As the market learned the truth about uniQure, investors faced substantial losses, prompting the Schall Law Firm to encourage affected shareholders to join the lawsuit for compensation, reflecting serious issues regarding the company's transparency and compliance.
See More
uniQURE Faces Class Action Lawsuit
- Lawsuit Background: Kirby McInerney LLP has announced a class action lawsuit on behalf of investors who acquired uniQURE N.V. securities between September 24, 2025, and October 31, 2025, alleging that the company failed to fully disclose FDA approval of its Pivotal Study design, potentially leading to investor losses.
- Stock Price Plunge: Following the disclosure on November 3, 2025, that the timeline for the BLA submission was unclear, uniQURE's stock price plummeted by $33.40, or approximately 49.33%, from $67.69 on October 31, 2025, reflecting strong market concerns about the company's future prospects.
- Investor Rights: Any investor who purchased shares during the class period can seek appointment as lead plaintiff in the class action lawsuit, with courts typically appointing those with the largest financial losses, ensuring that investor rights are protected throughout the legal process.
- Legal Consultation Opportunity: Kirby McInerney LLP offers no-cost legal consultations, encouraging affected investors to reach out to understand their rights and interests, indicating the firm's commitment to securing compensation for investors.
See More
